Polish Radio reports results for amycretin, another obesity candidate in Novo's pipeline. Details are at the source.
Recap by typeshit. Full story at www.polskieradio.pl.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
BusinessWorld Online covers a Lilly weight loss drug still in clinical trials. Few details were given beyond the headline.
A short social post says drugs like Ozempic may lower heart attack and stroke risk, possibly beyond what weight loss alone explains.
A post hoc look at phase 3 ICONIC data found similar efficacy, safety and drug levels in 31 GLP-1 users. The researchers note the small sample limits the conclusions.
Reuters talks to users like Allison Vecchio, 42, who take supplements for GLP-1 side effects such as stomach trouble and brittle nails, while doctors and regulators voice caution.
Loading…